ReviewJournal of cancer research and clinical oncology2025
Retrospective analysis of asparaginase-associated pancreatitis in pediatric acute lymphoblastic leukemia: focus on rechallenge with pegaspargase.
Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- L-asparaginase by filamentous fungi and yeasts from lichens and soils across maritime Antarctic islands.Extremophiles : life under extreme conditions · 2026Article
- Acute Pancreatitis Complicating L-asparaginase Therapy in Pediatric Oncology: A Case Report.Cureus · 2026Article
- Nomogram-based prediction of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a retrospective study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe incidence of asparaginase-associated pancreatitis (AAP) in children with acute lymphoblastic leukemia (ALL) may lead to treatment delays and insufficient drug exposure, thereby increasing the risk of ALL relapse. We aimed to understand the clinical characteristics and management of AAP, which are crucial for improving treatment outcomes in children with ALL.
methodsWe retrospectively analyzed the medical records of children diagnosed with AAP and admitted to Hebei Children's Hospital between April 2019 and July 2024. We analyzed the clinical characteristics and management strategies of AAP in children with ALL, with a particular focus on the treatment strategies and AAP recurrence in children who were rechallenged with pegaspargase (PEG-ASP).
resultsAmong 474 patients treated for ALL, 32 were diagnosed with AAP (incidence rate, 6.8%). Of these 32 cases, mild pancreatitis accounted for 50.0% (16/32), moderately severe pancreatitis for 43.8% (14/32), and severe pancreatitis for 6.3% (2/32). AAP occurred most frequently during the induction and early intensive therapy phases. The median time to onset of AAP was 10.5 (1-26) days, and the median number of PEG-ASP doses administered was three (range 1-11). Notably, 53.1% (17/32) patients were rechallenged with PEG-ASP, of whom seven experienced AAP recurrence, including one with three episodes. Despite these statuses, all patients either recovered or showed improvement in their disease status, and no mortality was reported.
conclusionAAP in children with ALL can be effectively managed through early detection and appropriate treatment. Rechallenge with PEG-ASP should be individualized to balance the risk of recurrence against the benefits of continued therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.